

Urška Nabergoj Makovec, Mitja Kos

University of Ljubljana, Faculty of Pharmacy, Aškerčeva 7, 1000 Ljubljana, Slovenia

E-mail: urska.nabergoj.makovec@ffa.uni-lj.si, Web: www.ffa.uni-lj.si

7th PCNE Working Symposium, 7 - 8 February 2020, Egmond aan Zee, the Netherlands

Background


Identification of drug related problems (DRPs) and activities to resolve them are among the goals of the Medicines Use Review (MUR) service in Slovenia.

Purpose

We aimed to evaluate the extent and nature of identified DRPs and to explore MUR effect on them.

Methods

Figure 1: Study design of the randomized controlled trial.



1

Descriptive analysis

- Classification of DRPs with DRP-SLO-V1¹

1. Horvat N, Kos M. Development and validation of the Slovenian drug-related problem classification system based on the PCNE classification V 6.2. Int J Clin Pharm (2016) 38: 950.

2

A before-after analysis - changes between visits in:

- proportion of manifested DRPs
- proportion of patients with at least one manifested DRP,
- proportion of patients with change in manifested DRP risk level

one sample binomial test ($\alpha=0.05$)

- no new DRPs (manifested or potential) arose between the visits
- DRPs of dropout patients and DRPs with unknown outcomes were excluded
- risk level = $\sum_{\text{manifested DRP}} (\text{solved}=1.0; \text{partially solved}=0.5; \text{unsolved}=0)$

Findings

Sample characteristics

1

39 to 86 years old
63,6 % female; 87 % retired
7 (2-13) regularly used Rx medicines

77 patients at visit 1
72 patients at visit 2

221 identified DRPs

→ 90 manifested DRPs (40,7 %)

■ Only potential DRPs ■ Only manifested DRPs ■ Potential and manifested DRPs




Figure 2: Proportions of patients with identified DRPs per DRP type at visit 1 (N=77).

Table 1.: The nature of identified manifested DRPs at visit 1 (N=90).

	N	%
P1 Treatment effectiveness	17	18.9%
P1.1 No effect of drug treatment/therapy failure.	1	1.1%
P1.2 Effect of drug treatment not sufficient or too weak.	8	8.9%
P1.3 Untreated symptoms or indication.	8	8.9%
P2 Adverse drug event	54	60.0%
P2.1 Adverse drug event due to allergic reaction.	1	1.1%
P2.2 Other adverse drug event.	53	58.9%
P3 Treatment costs	11	12.2%
P3.1 Drug treatment more costly than necessary.	8	8.9%
P3.2 Unnecessary drug-treatment.	3	3.3%
P4 Others	8	8.9%
P4.1 Patient dissatisfied with therapy despite optimal clinical and economic treatment outcomes.	1	1.1%
P4.2 Unclear problem/complaint.	7	7.8%

2

Proportion of manifested DRPs ($N_{\text{total}}=131$)

Visit 1

55.7%

$p = 0.001$

Visit 2

42.0%

Proportion of patients with at least one manifested DRP ($N_{\text{total}}=68$)

61.8%

$p < 0.001$

41.2%

Proportion of patients with change in manifested DRP risk level ($N_{\text{total}}=68$)

61.8%

$p < 0.001$

14.7%

Conclusion

Large number of identified as well as resolved manifested DRPs, show beneficial and positive impact of the MUR service in Slovenia.